Picking a CDMO for OEB 4 or OEB 5 compounds isn’t a price exercise. Get it wrong and you could face exposed operators, a failed inspection, or a programme that has to move sites halfway through. So before you compare quotes, compare evidence. This guide walks through how to screen a CDMO from the buyer’s side: what to confirm about your own compound first, seven areas worth testing, the questions to ask, and the signs it’s time to walk away.
New to the topic? Our guide to OEB Level-5 containment in oncology manufacturing covers what a properly assessed facility looks like. This post is the next step: how to compare CDMOs against that standard.
Start With Your Own Compound
Most selection problems begin on the buyer’s side, not the CDMO’s. Before you email anyone, pull together what you actually know: any OEL, potency data, the safety data sheet, and whatever hazard assessment has already been done.
Then check who assigned your OEB band. A band from your own EHS team, an outside consultant or the compound’s originator all carry different weight, and you should know which one you’re holding.
Also write down the definition behind the number. Cut-offs aren’t universal, so one company’s OEB 5 can be another’s OEB 4 or OEB 6. Skip this and you’ll end up comparing CDMOs against different yardsticks without realising it. For more on the bands, see OEB classification in pharma.
And if your data is thin? Resist the urge to pick a lower band so more CDMOs qualify. Ask a toxicologist or containment specialist for a provisional band, and treat it cautiously until you know more.
“OEB 5 Capable” Means Nothing Without a Scope
Almost every oncology CDMO says yes when you ask about OEB 5. The better question is: yes to what?
One site might run the full chain inside a dedicated suite. Another might only dispense in an isolator. Both put “OEB 5” on the website. So ask for the scope in writing: which bands, which dosage forms and process steps, which suites or buildings, and what independent evidence sits behind the claim.
Seven Areas Worth Testing
1. Containment Evidence
Ask to see the independent containment assessment, the latest isolator performance data and the date of the test. Then actually read the scope. A general facility certificate doesn’t tell you much if it doesn’t cover your compound class and your process steps. Our 4-step verification checklist lists exactly what to request.
2. Suite Design and Segregation
Look at how the HPAPI area is separated from the rest of the plant: air handling, pressure cascade, airlocks, and the way people, product and waste move through. Then ask about changeover between compounds. A shared suite isn’t automatically a problem. It does need cross-contamination controls that someone can explain and defend for your molecule.
3. Process and Dosage Form Fit
Containment skills don’t transfer neatly between process types. A site that’s excellent at oral solids may have little to offer on API manufacture or ADC payload handling (see ADC payload containment requirements). Check the dosage form, whether you need API or formulation or both, and the scale you’re heading for, from clinical to commercial. Ask for comparable programmes, within what confidentiality allows.
4. Cleaning Validation and Analytics
This is where a hardware-only investment shows. Ask for the cleaning validation master plan, swab recovery data and the methods used for trace-level detection. If a CDMO struggles to produce these, that tells you something. More detail in our guide to cleaning validation for OEB 5 compounds.
5. Regulatory and Inspection History
Find out which agencies have inspected the site (US FDA, MHRA, EMA, ANVISA and so on) and how it went. Ask how any observations about containment or cross-contamination were closed out. GMP approval and containment capability are two separate checks, and you need both.
6. Occupational Health and HSE
Ask about training before first handling, respiratory protection for work outside isolators, medical surveillance, and how exposure incidents are recorded and followed up. A mature team answers openly and in detail. Hesitation is useful information.
7. Project Governance and Supply
A great suite doesn’t help if the technical transfer plan is vague or API supply is shaky. Ask about the transfer process, the quality agreement, change control, where API comes from (in-house, a group company or a third party) and how scale-up will be handled.
[ADD: 2 to 3 sentences from Pinnacle’s QA or EHS team on what they personally look for when they audit a containment suite, or the question they find most revealing. Real experience goes here.]
A Simple Scoring Matrix
A weighted matrix keeps the decision documented and fair across candidates. The weights below are only a starting point. Agree your own with QA, EHS and procurement before anyone scores.
| Criteria | Example Weight | Strong answer |
|---|---|---|
| Containment evidence | High | Dated independent assessment that covers your compound and steps |
| Suite design and segregation | High | Documented segregation and changeover controls |
| Process and dosage form fit | High | Comparable work at your scale |
| Cleaning and analytics | Medium to high | Validated methods, recovery data on request |
| Regulatory history | High | Relevant approvals, open about past observations |
| Occupational health and HSE | Medium to high | Detailed programme, records available |
| Governance and supply | Medium | Clear transfer plan, stable API source |
| Commercial terms and location | Medium | Competitive, but never the tiebreaker against safety |
Score each CDMO from 1 to 5 per row, multiply by the weight, and write down the evidence behind every number. One rule sits above the maths: a CDMO that fails on containment evidence drops off the list, whatever its total.
What to Ask on the First Call
Group your questions so the call doesn’t turn into a checklist recital.
Scope and evidence
- Which OEB bands do you handle, and whose band definition do you use?
- Which suites, dosage forms and steps does that cover?
- Who assessed your containment, and can we see the document and the latest isolator test result?
Cross-contamination and cleaning
- How do you control changeover between compounds?
- What are your cleaning acceptance limits based on, and how do you verify them?
Compliance and people
- Which regulators have inspected this site, and were there containment-related observations?
- What respiratory protection and medical surveillance do operators follow, and how are exposure incidents escalated?
Fit and delivery
- Have you worked with our dosage form and scale before?
- Where does the API come from?
- Can our QA and EHS leads audit the site before we sign?
Red Flags
Some things should slow you down straight away:
- No independent containment assessment, or a polite refusal to share it
- A certificate with no stated scope, or one that’s out of date
- Fuzzy answers when you ask how cleaning limits were set
- A shared suite with no clear changeover procedure
- Any hesitation about a site audit
- Containment claims that don’t match the steps your process needs
- Pressure to sign before diligence is done
One red flag means dig deeper. Several together mean walk away.
Building the Shortlist
Directory searches rarely give you reliable capability data. You’ll do better by asking your containment or EHS advisor which facilities they’ve assessed, reviewing regulatory inspection records, and talking to peers who’ve run similar programmes. Then send every candidate the same structured RFI so you can compare like with like.
Geography matters less than people expect. Approvals, containment record and project fit should drive the shortlist, with logistics and cost coming after. For a wider look at the Indian market, see Pharmaceutical Contract Manufacturers in India: Complete Guide 2026.
How the Selection Process Usually Runs
Start with the RFI and document requests. Under NDA, share enough compound data for a proper hazard review. Move to a technical proposal and compare process fit, containment approach and timelines. Then send QA and EHS to audit the site (our CDMO audit preparation guide helps here). Before manufacturing starts, agree the quality agreement and technical transfer plan, and consider a pilot or engineering batch to confirm performance before scale.
If you want the wider picture of where manufacturing sits in a programme, read Oncology Drug Development Process: Every Stage, and Where Manufacturing Fits In and Pharmaceutical Contract Manufacturing: A Plain Guide for Drug Companies.
Where Pinnacle Life Science Fits
We’re an oncology-focused CDMO headquartered in Mumbai, with a US FDA-approved facility in Baddi, Himachal Pradesh. Our high-potency oncology oral solid dosage work runs from API dispensing through granulation, tablet compression, film coating and primary packaging inside isolator systems, and being part of Aarti Drugs Ltd gives us an integrated API supply chain.
Don’t take our word for it. Run this framework on us too, ask for the evidence, and talk to our HPAPI team about your compound.
Frequently Asked Questions
What should I look at first when choosing a CDMO for OEB 4 or OEB 5 compounds?
Your own compound. Confirm its OEB band and who assigned it. Then test each CDMO on containment evidence, suite design, process fit, cleaning, regulatory history, occupational health and project governance, and audit the site before you sign.
How do I check a CDMO’s OEB 5 claim?
Ask for the independent containment assessment with its scope and date, the latest isolator performance test and the cleaning validation master plan. Then walk the site with your QA and EHS leads.
Is a GMP-approved CDMO automatically OEB 5 capable?
No. GMP approval covers quality and process control. OEB 5 capability is a separate containment question. A CDMO handling OEB 5 compounds needs both.
Which CDMOs can handle OEB 5 and OEB 6 compounds?
Not many can show verified capability at those bands. Build your list from independent assessments, inspection records and peer references, not from website claims.
Should I pick an OEB 5 CDMO for an OEB 4 compound?
Not by default. What matters is verified capability that matches your confirmed band, plus experience with your dosage form and scale. A higher-spec site that has never run your process type isn’t automatically the safer choice.
What are the biggest red flags with an HPAPI CDMO?
No independent assessment, an out-of-scope or expired certificate, vague cleaning answers, unclear changeover controls and reluctance to allow an audit.
Evaluating CDMOs for an OEB 4 or OEB 5 Programme?
Tell us about your compound, its band and your timeline. Contact Pinnacle Life Science.
